OCUL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ocular Therapeutix Inc (OCUL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including FDA alignment for its Axpaxli NDA submission, bullish analyst ratings with increased price targets, and significant hedge fund buying activity. While insider selling and recent financial losses are concerns, the long-term growth potential and regulatory progress outweigh the negatives.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 67.392, and moving averages are converging, suggesting a potential breakout. Key support is at 8.21, and resistance levels are at 9.981 and 10.529. The technical indicators suggest the stock is poised for upward movement.
FDA alignment for Axpaxli NDA submission in Q4
Analysts have raised price targets significantly (H.C. Wainwright: $25, Baird: $
and maintained Buy/Outperform ratings.
Hedge funds are heavily buying, with a 2312.47% increase in buying activity over the last quarter.
Insiders are selling, with a 186.05% increase in selling activity over the last month.
Financial performance shows a decline in revenue (-18.7%) and a significant net loss of $265.9 million for FY 2025.
Ocular Therapeutix reported $51.8 million in revenue for FY 2025, a decline of 18.7%. The company also reported a net loss of $265.9 million, reflecting challenges in profitability. However, the focus on Axpaxli's regulatory progress may drive future growth.
Analysts are bullish on OCUL. H.C. Wainwright raised the price target to $25 from $21 and Baird increased it to $30 from $24, citing strong regulatory progress and potential market adoption for Axpaxli.
